{arrow_up} Back to top

Risk Minimisation Materials

Search by company, common medicine name, or title of Risk Minimisation Material

MabThera

Roche Products Limited

{pdf_link}

MabThera (rituximab) in Non-Oncology Indications Patient Alert Card

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

MaloffProtect

Glenmark Pharmaceuticals Europe Ltd

{pdf_link}

Maloff Protect - Pack Size Calculator

A quick reference guide to the appropriate Maloff Protect pack sizes for trips to malaria endemic areas

{pdf_link}

Maloff Protect - Pharmacy Checklist

{healthcare_pro_orange} For Healthcare Professionals
A quick guide to the key actions the pharmacist should take before supplying Maloff Protect

{pdf_link}

Maloff Protect - Pharmacy Guide

{healthcare_pro_orange} For Healthcare Professionals
This guide provides information on the correct choice and usage of the various malaria chemoprophylaxis, including Maloff Protect

{pdf_link}

Maloff Protect - Pharmacy Screening Questionnaire and Explanatory Sheet

{healthcare_pro_orange} For Healthcare Professionals
A screening questionnaire which the pharmacist can fill out with the customer. It is accompanied by some explanatory notes and together these will help the pharmacist understand if Maloff Protect is suitable for the customer.

{pdf_link}

Maloff Protect - User Reminder Card

Along with the User Reminder App, customers can use this Reminder Card to plan their Maloff Protect dosing

Matrifen

Takeda UK Ltd

{pdf_link}

Transdermal fentanyl (“patches”)

{healthcare_pro_orange} For Healthcare Professionals
Reminder of the potential risk of life-threatening harm from accidental exposure

Mavenclad

Merck

{pdf_link}

MAVENCLAD 10 mg Tablets (cladribine) - Patient Guide

MAVENCLAD 10 mg Tablets (cladribine) - Patient Guide - Important information on minimising the risk of adverse events

{pdf_link}

MAVENCLAD 10 mg Tablets (cladribine) - Prescriber's Guide

{healthcare_pro_orange} For Healthcare Professionals
MAVENCLAD 10 mg Tablets (cladribine) - Prescriber's Guide - Important information on minimising the risk of adverse events

Maxtrex

Pfizer Limited

{pdf_link}

Educational Materials for Healthcare Professionals: Medicines containing Methotrexate

{healthcare_pro_orange} For Healthcare Professionals
To minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases

{pdf_link}

Methotrexate Patient Alert Card - Information for Patients

The Patient Card contains important safety information the patient needs to be aware of when receiving treatment with methotrexate for conditions including arthritis and psoriasis

Mayzent

Novartis Pharmaceuticals UK Ltd

{pdf_link}

Mayzent (siponimod) - Patient & Caregiver Medical Information Guide - for patients and caregivers

This guide contains important information about MAYZENT® (siponimod) dosing, side effects and their potential risks, including guidance on pregnancy

{pdf_link}

Mayzent (siponimod) - Pregnancy Reminder Card - for patients

This Pregnancy Reminder Card contains information for female patients of childbearing potential

{pdf_link}

Mayzent (siponimod) - Prescriber Checklist - For Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals
This guide provides essential information on the most important risks associated with Mayzent and the activities required to minimise these risks. It is advised that this guide is read alongside the summary of product characteristics

Mefloquine

Neon Healthcare Ltd

{pdf_link}

Checklist for Healthcare Professionals (Mefloquine)

{healthcare_pro_orange} For Healthcare Professionals
Checklist for the prescription, supply or recommendation of mefloquine for malaria chemoprophylaxis

{pdf_link}

Guide for Healthcare Professionals (Mefloquine)

{healthcare_pro_orange} For Healthcare Professionals
This guide is intended to provide you with information regarding side effects which may be associated with chemoprophylactic use of mefloquine.

{pdf_link}

Patient Alert Card (Mefloquine)

Patient Alert Card for Mefloquine

Methotrexate

ADVANZ Pharma

{pdf_link}

Methotrexate Educational Materials for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals
Methotrexate Educational Materials for Healthcare Professionals approved by the MHRA

{pdf_link}

Methotrexate Patient Card

{healthcare_pro_orange} For Healthcare Professionals
card approved by MHRA.

Cipla EU Ltd

{pdf_link}

Educational Materials for Healthcare Professionals - Methotrexate

{healthcare_pro_orange} For Healthcare Professionals
To minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases

{pdf_link}

Patient Alert Card - Methotrexate

{healthcare_pro_orange} For Healthcare Professionals
The Patient Card contains important safety information the patient needs to be aware of when receiving treatment with methotrexate for conditions including arthritis and psoriasis.

Hospira UK Ltd

{pdf_link}

Educational Materials for Healthcare Professionals: Medicines containing Methotrexate

{healthcare_pro_orange} For Healthcare Professionals
To minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases

{pdf_link}

Methotrexate Patient Alert Card - Information for Patients

The Patient Card contains important safety information the patient needs to be aware of when receiving treatment with methotrexate for conditions including arthritis and psoriasis.

Morningside Healthcare Ltd

{pdf_link}

Methotrexate - Educational Materials for Healthcare Professionals - Medicines containing Methotrexate

{healthcare_pro_orange} For Healthcare Professionals
To minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases Medicines containing methotrexate are available in a range of presentations, including: oral tablets, oral solutions, vials for injection, pre‐filled syringes and pens for injection, concentrate for solution for injection.

{pdf_link}

Methotrexate Patient Alert Card - Information for Patients

THIS PATIENT CARD IS ONLY INTENDED FOR PATIENTS TAKING METHOTREXATE ONCE A WEEK FOR CONDITIONS INCLUDING ARTHRITIS, PSORIASIS AND CROHN'S DISEASE.

Orion Pharma (UK) Limited

{pdf_link}

Educational Materials for Healthcare Professionals - Medicines containing Methotrexate

{healthcare_pro_orange} For Healthcare Professionals
A guide for Healthcare Professionals to minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases.

{pdf_link}

Methotrexate Patient Alert Card - Information for Patients

The Patient Card contains important safety information the patient needs to be aware of when receiving treatment with methotrexate for conditions including arthritis and psoriasis.

Rosemont Pharmaceuticals Limited

{pdf_link}

Guide for Healthcare Professionals Rosemont Methotrexate 2 mg/ml Oral Solution

{healthcare_pro_orange} For Healthcare Professionals
Educational Materials. Guide for Healthcare Professionals Rosemont Methotrexate 2 mg/ml Oral Solution

Sandoz Limited

{pdf_link}

Educational materials for Healthcare Professionals - medicines containing Methotrexate

{healthcare_pro_orange} For Healthcare Professionals
To minimise the risk of overdose from patients incorrectly taking methotrexate daily instead of once weekly for autoimmune diseases

{pdf_link}

Patient Reminder Card - Methotrexate

This Patient Card is only intended for patients taking Methotrexate once a week for conditions including arthritis, psoriasis and Crohn's Disease.

Methylphenidate

Mylan

{external_link}

Physician's Guide to Prescribing Methylphenidate Hydrochloride

{healthcare_pro_orange} For Healthcare Professionals
Prescribing checklist before prescribing methylphenidate hydrochloride and checklist for ongoing monitoring

Mexiletine

Clinigen Healthcare Ltd

{pdf_link}

Mexiletine Hydrochloride 50, 100 and 200 mg Hard Capsules – HCP guide on minimising the risks of cardiac adverse events and severity of adverse reactions in those with hepatic impairment

{healthcare_pro_orange} For Healthcare Professionals

HCP guide on minimising the risks of cardiac adverse events and severity of adverse reactions in those with hepatic impairment


Micafungin

Flynn Pharma Ltd

{pdf_link}

Micafungin: safety checklist for prescribing physicians

{healthcare_pro_orange} For Healthcare Professionals
Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine

Wockhardt UK Ltd

{pdf_link}

Prescriber Checklist

{healthcare_pro_orange} For Healthcare Professionals
Checklist

Microgynon

Bayer plc

{pdf_link}

CHCs - Checklist for Prescribers

{healthcare_pro_orange} For Healthcare Professionals
Combined Hormonal Contraceptives - checklist for prescribers

{pdf_link}

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

{pdf_link}

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

Microgynon ED

Bayer plc

{pdf_link}

CHCs - Checklist for Prescribers

{healthcare_pro_orange} For Healthcare Professionals
Combined Hormonal Contraceptives - checklist for prescribers

{pdf_link}

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

{pdf_link}

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

Millinette

Gedeon Richter (UK) Ltd

{pdf_link}

Checklist for Prescribers

{healthcare_pro_orange} For Healthcare Professionals
Checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.

{pdf_link}

Patient User Card

Important information for women about risk of blood clots with combined hormonal contraceptives (CHC).

Mintreleq

Aristo Pharma Limited

{pdf_link}

Mintreleq XL (Quetiapine MR) Risk Management Plan for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals
Information for Healthcare Professionals to help inform patients, their families, and their caregivers about the benefits and the risks associated with quetiapine treatment.

Mirena

Bayer plc

{pdf_link}

Bayer Intrauterine System (IUS) Educational Pack

{healthcare_pro_orange} For Healthcare Professionals
Healthcare professional brochure to describe risk of ectopic pregnancy and how to differentiate between Bayer levonorgestrel IUS (LNG-IUS)

Monofer

Pharmacosmos UK Limited

{pdf_link}

HCP Educational Material Ferric Derisomaltose

{healthcare_pro_orange} For Healthcare Professionals
IV iron. Essential Prescription and Administration Information to Minimise the Risk of Serious Hypersensitivity Reactions

{pdf_link}

Patient Educational Material Ferric derisomaltose

Intravenous (IV) Iron. Important Information for Patients about the Possible Risk of Serious Allergic Reactions with IV iron treatment (iron given by injection or infusion into a vein)

Multaq

SANOFI

{pdf_link}

Multaq - Prescriber Guide

{healthcare_pro_orange} For Healthcare Professionals
For hard copies, please contact medical information department at 0800 035 2525 or email [email protected].

Myalepta

Amryt Pharmaceuticals DAC

{pdf_link}

Myalepta (metreleptin) Healthcare Professional Guide

{healthcare_pro_orange} For Healthcare Professionals
Healthcare professional guide contains information on the specific risks associated with Myalepta and the measures designed to address them along with the potentially serious adverse drug reactions.

{pdf_link}

Myalepta (metreleptin) Patient Care Guide

This document contains important risk minimisation information for patients and their carers.

{pdf_link}

Myalepta (metreleptin) Patient Dose Information Card

Provides patients and their carers important information on how to reconstitute and administer Myalepta (metreleptin).

{pdf_link}

Myalepta (metreleptin) Specialist Prescriber Guide

{healthcare_pro_orange} For Healthcare Professionals
This brochure is for Specialist Prescribers of Myalepta only and provides guidance on determining the right dose, training the patient to prepare and inject and prescribing.

Mycophenolate

Rosemont Pharmaceuticals Limited

{pdf_link}

Mycophenolate Guide for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals
Mycophenolate Guide for Healthcare Professionals- Information about Risk of Teratogenicity

{pdf_link}

Mycophenolate Guide for Patients

Mycophenolate Guide for Patients Information- about risks to the unborn baby

Tillomed Laboratories Ltd

{pdf_link}

Mycophenolate mofetil 250mg Capsules Guide for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals
Guide for Healthcare Professionals

{pdf_link}

Mycophenolate mofetil 500mg film-coated Tablets Guide for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals
Guide for Healthcare Professionals

Mycophenolate mofetil

Teva Pharma B.V.

{pdf_link}

Mycophenolate Mofetil (Myfenax) Guide for Healthcare Providers

{healthcare_pro_orange} For Healthcare Professionals
This Guide has been designed to highlight the risks to babies associated with exposure to mycophenolate during pregnancy and to minimise the number of pregnancies during treatment with this teratogenic medicinal products. Use this guide during, discussion with the patient to address any questions or concerns the patient may have. Although this Guide presents important information concerning the adverse pregnancy outcomes associated with mycophenolate, please consult the Summary of Product Characteristics (SmPC) for full information on mycophenolate.

{pdf_link}

Mycophenolate mofetil (Myfenax): risks of miscarriage and birth defects Patient Guide

This guide will help you to remember the information you have discussed with your doctor. Keep it so that you can refer to it again. Also, read the package leaflet supplied with your medicine for full information on mycophenolate mofetil.

Myfortic

Novartis Pharmaceuticals UK Ltd

{pdf_link}

Myfortic (Mycophenolic acid) - Guide for Healthcare Providers - Risk of teratogenicity

{healthcare_pro_orange} For Healthcare Professionals
This guide has been designed to highlight the risks associated with exposure to mycophenolate during pregnancy, as well as the measures that should be taken to mitigate them.

{pdf_link}

Myfortic (mycophenolic acid) - Guide for Patients - Information about the risks to the unborn baby

This guide is about the risks of mycophenolate for the unborn baby, and the ways to reduce these risks.

Myozyme

SANOFI

{pdf_link}

Myozyme (alglucosidase alfa) - Home Infusion HCP Manual - Risk Minimisation Information

{healthcare_pro_orange} For Healthcare Professionals
For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

{pdf_link}

Myozyme (alglucosidase alfa) - Safety Information Packet (SIP) - Risk Minimisation Information for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals

IMPORTANT INFORMATION for healthcare professionals on risks associated with alglucosidase alfa administration, clinical management of infusion-associated reactions, immune-mediated reactions and immunology testing


{pdf_link}

Myozyme (alglucosidase alfa) - Home Infusion Patient and Caregivers Manual - Risk Minimisation Information

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Mysimba

Orexigen Therapeutics Ireland Limited

{pdf_link}

Physician Prescribing Checklist

{healthcare_pro_orange} For Healthcare Professionals
This checklist is provided by Orexigen Therapeutics Ireland Limited as a requirement under the terms of the marketing authorization for this medicine. This prescriber guide is a reminder of the indication, contraindications, warnings and precautions as well as the patient characteristics that may place patients at higher risk of adverse reactions to Mysimba. This will help ensure appropriate patient selection and remind physicians of patients who should not be prescribed Mysimba or in whom it should be used with caution. This checklist should be completed prior to initiating therapy with Mysimba.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?